Literature DB >> 22538649

Microbial fingerprinting detects unique bacterial communities in the faecal microbiota of rats with experimentally-induced colitis.

Ashis K Samanta1, Valeria A Torok, Nigel J Percy, Suzanne M Abimosleh, Gordon S Howarth.   

Abstract

An abnormal composition of the gut microbiota is believed to be associated with the pathogenesis of inflammatory bowel disease (IBD). We utilized terminal restriction fragment length polymorphism (T-RFLP) analysis to quantify faecal bacterial communities from rats with experimental colitis. Male Sprague Dawley rats (n=10/group) ingested 2% dextran sulfate sodium (DSS) or water for up to 7 days. Rats were killed and colonic tissues collected for histological analysis. Damage severity score in the distal colon was significantly greater (P<0.001) following DSS consumption compared to controls. T-RFLP faecal bacterial profiles generated with either MspI or CfoI revealed a significant difference (P<0.001) in community composition between healthy and colitic rats, with bacterial composition in healthy rats more variable than in rats with colitis. Operational taxonomic units (OTU: taxonomically related groups of bacteria) associated with either the healthy or colitic state were identified. OTU (116, 226, 360, and 948; CfoI) and (118 and 188; MspI) were strongly associated with untreated healthy rats, while OTU (94, 98, 174, and 384; CfoI) and (94 and 914; MspI) were predominantly associated with DSS-treated colitic rats. Phylogenetic OTU assignment suggested that Bacteroidales and Lactobacillus sp. were predominantly associated with the colitic and healthy rats, respectively. These results show that faecal bacterial profiling is a rapid, sensitive and non-invasive tool for detecting and identifying changes in gut microbiota associated with colitis. Restoring microbial homeostasis by targeting colitis-associated OTU through specific microbiological interventions could form the basis of novel therapeutic strategies for IBD.

Entities:  

Mesh:

Year:  2012        PMID: 22538649     DOI: 10.1007/s12275-012-1362-8

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  43 in total

1.  A novel strategy to extract specific phylogenetic sequence information from community T-RFLP.

Authors:  Franco Widmer; Martin Hartmann; Beat Frey; Roland Kölliker
Journal:  J Microbiol Methods       Date:  2006-03-06       Impact factor: 2.363

Review 2.  What immunologists should know about bacterial communities of the human bowel.

Authors:  Gerald W Tannock
Journal:  Semin Immunol       Date:  2006-10-10       Impact factor: 11.130

3.  Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy.

Authors:  S L Gorbach; L Nahas; A G Plaut; L Weinstein; J F Patterson; R Levitan
Journal:  Gastroenterology       Date:  1968-04       Impact factor: 22.682

4.  Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease.

Authors:  Shadi Sepehri; Roman Kotlowski; Charles N Bernstein; Denis O Krause
Journal:  Inflamm Bowel Dis       Date:  2007-06       Impact factor: 5.325

5.  Molecular fingerprinting of the fecal microbiota of children raised according to different lifestyles.

Authors:  Johan Dicksved; Helen Flöistrup; Anna Bergström; Magnus Rosenquist; Göran Pershagen; Annika Scheynius; Stefan Roos; Johan S Alm; Lars Engstrand; Charlotte Braun-Fahrländer; Erika von Mutius; Janet K Jansson
Journal:  Appl Environ Microbiol       Date:  2007-02-09       Impact factor: 4.792

Review 6.  Prebiotics, synbiotics and inflammatory bowel disease.

Authors:  Helen Steed; George T Macfarlane; Sandra Macfarlane
Journal:  Mol Nutr Food Res       Date:  2008-08       Impact factor: 5.914

7.  Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis.

Authors:  Akira Andoh; Shinji Sakata; Yuhsuke Koizumi; Keiichi Mitsuyama; Yoshihide Fujiyama; Yoshimi Benno
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

8.  Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice.

Authors:  Roger Yazbeck; Gordon S Howarth; Mark S Geier; Hans-Ulrich Demuth; Catherine A Abbott
Journal:  Front Biosci       Date:  2008-05-01

9.  The rectal mucosa-associated microflora in patients with ulcerative colitis.

Authors:  M G Hartley; M J Hudson; E T Swarbrick; M J Hill; A E Gent; M D Hellier; R H Grace
Journal:  J Med Microbiol       Date:  1992-02       Impact factor: 2.472

10.  The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.

Authors:  J D Taurog; J A Richardson; J T Croft; W A Simmons; M Zhou; J L Fernández-Sueiro; E Balish; R E Hammer
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  23 in total

1.  Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.

Authors:  Enzo Spisni; Maria C Valerii; Luigia De Fazio; Elena Cavazza; Francesca Borsetti; Annamaria Sgromo; Marco Candela; Manuela Centanni; Fernando Rizello; Antonio Strillacci
Journal:  Mol Ther       Date:  2014-11-13       Impact factor: 11.454

2.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

3.  Changes in intestinal barrier function and gut microbiota in high-fat diet-fed rats are dynamic and region dependent.

Authors:  M Kristina Hamilton; Gaëlle Boudry; Danielle G Lemay; Helen E Raybould
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-06       Impact factor: 4.052

4.  Deodorization of pig slurry and characterization of bacterial diversity using 16S rDNA sequence analysis.

Authors:  Ok-Hwa Hwang; Sebastian Raveendar; Young-Ju Kim; Ji-Hun Kim; Jung-Woo Choi; Tae-Hun Kim; Dong-Yoon Choi; Che Ok Jeon; Sung-Back Cho; Kyung-Tai Lee
Journal:  J Microbiol       Date:  2014-10-31       Impact factor: 3.422

Review 5.  Natural compounds as safe therapeutic options for ulcerative colitis.

Authors:  Mukta Gupta; Vijay Mishra; Monica Gulati; Bhupinder Kapoor; Amrinder Kaur; Reena Gupta; Murtaza M Tambuwala
Journal:  Inflammopharmacology       Date:  2022-02-25       Impact factor: 4.473

6.  Longitudinal analysis of inflammation and microbiota dynamics in a model of mild chronic dextran sulfate sodium-induced colitis in mice.

Authors:  Luigia De Fazio; Elena Cavazza; Enzo Spisni; Antonio Strillacci; Manuela Centanni; Marco Candela; Chiara Praticò; Massimo Campieri; Chiara Ricci; Maria Chiara Valerii
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

7.  Assessment of Fecal Microflora Changes in Pigs Supplemented with Herbal Residue and Prebiotic.

Authors:  Ashis Kumar Samanta; C Jayaram; N Jayapal; N Sondhi; A P Kolte; S Senani; M Sridhar; A Dhali
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

8.  Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease.

Authors:  Yanmin Guo; Guangxi Zhou; Chong He; Wenjing Yang; Zhenkun He; Zhanju Liu
Journal:  Mediators Inflamm       Date:  2015-05-28       Impact factor: 4.711

9.  Characterization of the omlA gene from different serotypes of Actinobacillus pleuropneumoniae: A new insight into an old approach.

Authors:  Ciro César Rossi; Elza Fernandes de Araújo; Marisa Vieira de Queiroz; Denise Mara Soares Bazzolli
Journal:  Genet Mol Biol       Date:  2013-04-09       Impact factor: 1.771

10.  Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis.

Authors:  Chil-Sung Kang; Mingi Ban; Eun-Jeong Choi; Hyung-Geun Moon; Jun-Sung Jeon; Dae-Kyum Kim; Soo-Kyung Park; Seong Gyu Jeon; Tae-Young Roh; Seung-Jae Myung; Yong Song Gho; Jae Gyu Kim; Yoon-Keun Kim
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.